Newly Emerging Immunotherapy for Pancreatic Cancer Treatment
Status:
NOT_YET_RECRUITING
Trial end date:
2027-04-30
Target enrollment:
Participant gender:
Summary
This is a Phase Ib/II platform clinical study to evaluate the initial efficacy and safety of different novel immunotherapies in patients with advanced pancreatic cancer.